The results of the US CTN1506 trial examining the impact of post‐transplant gilteritinib maintenance therapy in patients allografted for Flt3+ AML is therefore eagerly awaited (NCT02997202) (Levis et al., 2019). Here, FLT3 is linked to acute myeloid leukemia.